Trade agreements between countries have a perceivable impact on access to medicines as a result of changes in patent and other national laws in different countries.
Through this deal, Swiss pharmaceutical corporations are working to erode India’s ability to produce and supply generic medicines for people across the developing world.
Negotiators must protect public health safeguards that enable developing countries like India to keep supplying life-saving affordable medicines for millions of people worldwide.
RCEP magnifies existing inequalities and discriminates against women, indigenous peoples, people living with HIV or other illnesses, people with disabilities,rural communities, farmers and workers
Trade unions, farmers groups, health activists, and other people’s movements are planning to organise a series of events to put pressure on the Government of India to withdraw from RCEP negotiations.
Granting data exclusivity for clinical trials would undermine access to medicines.
Switzerland is pushing for tighter patent protection, data exclusivity and dropping compulsory licencing under a new free trade agreement.
In this note, Switzerland is proposing that India agree to broader patentable subject matter, particularly as regards biologic products.
MSF and civil society urge Swiss negotiators not to undermine the ‘pharmacy of the developing world’
Concerns remain over the impact of RCEP negotiations on public health and access to medicines.
There is no principled basis for EU’s demand of extending patent protection beyond the period of 20 years.
The Trans-Pacific Partnership was dead long before Donald Trump signed his executive order. But its damaging aspects, like stringent IP provisions, have just migrated to other agreements
The pace of implementation of Indo-Japan free trade agreement needs to be further enhanced in order to exploit the huge potential of the pact, Commerce and Industry Minister Nirmala Sitharaman said.
India and the US continued to differ on the issue of intellectual property rights (IPR) norms in their bilateral trade and investment policy discussions
Member countries must consider the impact of RCEP on access to medicines in developing countries
As the next round of Regional Comprehensive Economic Partnership (RCEP) trade talks begin in Vietnam, humanitarian aid organisation Médecins Sans Frontières calls for the removal of intellectual property provisions from the agreement
A high-level panel hosted by India discusses the issues of trade deals that inhibit access to medicines and also limit policy space for governments to legislate in public interest.
The Ministry of Commerce must be cautious of Free Trade Agreements being negotiated with the European Union as well as the Regional Comprehensive Economic Partnership that further strengthen or extend intellectual property (IP) monopolies.
Of the RCEP negotiating countries, it is India, rather than China, that has been the most outspoken in opposing US-style trade rules.
Access to affordable medicines could be severely restricted for millions of people around the world under the current proposals in the Regional Comprehensive Economic Partnership (RCEP) trade agreement?